BIO 2014 Thursday Round-Up: Deal-Making Versus Internal Innovation
This article was originally published in The Pink Sheet Daily
As the BIO annual meeting wraps up its final day, plenty of things are still going on with participants discussing the value of R&D, as well as the deals in the headlines. Meanwhile, J&J announces a slew of tie-ups conducted through its Innovation Centers.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.